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1069progression. Unfortunately, in parallel with decreas-
ing funding opportunities, publishing in respected
journals has grown more difﬁcult. Thus, early career
academic cardiologists might greatly beneﬁt from
dedicated space in a high-impact journal such as
Journal of the American College of Cardiology (JACC).
There are important factors that need to be
considered carefully before launching an exclusively
early career journal. We should avoid the appearance
of an early career journal as a reservoir of less than
compelling research. Additionally, starting a journal
is a large undertaking that requires commitment of
resources from the American College of Cardiology
and our academic workgroup. In an environment of
limited means, a more effective use of resources is
to dedicate funding and mentorship to early career
cardiologists and trainees. With this support, early
career investigators will have greater chances of
publishing in well-respected pre-existing journals.
There are alternatives to launching a new journal
that still provide publication space for early career
members. For example, in JACC or one of its associated
journals, there could be a dedicated issue each year
or one paper per issue that highlights research of
emerging young investigators. Other paper types
include reviews or viewpoint pieces that particularly
address issues, challenges, and opportunities for early
stage investigators. Furthermore, we could ask early
career members to rotate on the editorial board to
ensure the review process has an early career perspec-
tive; this would also provide a valuable career devel-
opment opportunity for these junior investigators.
We appreciate the passion and the novel proposal
of Drs. Shenoy and Tuliani. It has stimulated our
workgroup to consider these important issues, which
we plan to discuss further with forthcoming recom-
mendations to promote greater development and
ﬂourishing of early stage investigators.*Carl W. Tong, MD, PhD
on behalf of the Early Career Academic Cardiologist
Workgroup of the American College of Cardiology
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Improve But the Scar Still
Exists! The Risk May Be
Lower But Not ZeroWe read with great interest the report by Kini et al. (1).
The results are interesting, and the authors make
a strong case against the clinical utility and cost-
effectiveness of continued generator replacements in
patients with implantable cardioverter-deﬁbrillators
who have improved ejection fraction (EF). We
disagree with the conclusions of the authors and ﬁnd
it rather bold to arrive at such sweeping recommen-
dations based on limited data. In this study, 8% (n ¼ 5)
of the 59 patients received appropriate therapy
despite improvement in EF over a mean of 3.5 years,
for an event rate of 2.8% per person-year or 1.4% per
year (n ¼ 5/3.5 years). This rate is much higher than
the 0.1% risk of sudden cardiac death in the general
population (2). If the general population is considered
a control group, then the absolute risk reduction is
1.3% with a number needed to treat of 76. With that
number needed to treat, we ﬁnd it hard to explain
the recommendation that a potentially lifesaving
therapy should be withheld. Again, if we consider all
patients who had an improvement in EF to >35%, we
would include the 8 patients who had an event before
generator replacement despite an EF >35%, which
would increase the event rate to 20% (n ¼ 13 of 67) or
3.7% per year. This reduces the number needed to
treat even further. Although EF, which is the surro-
gate marker for the risk of sudden cardiac death, may
improve over time, the scar that is the substrate for
reentry is unlikely to resolve, especially in patients
with ischemic cardiomyopathy (3). The cost-effective
analysis used in the current paper is not robust
either. Thus, until larger studies are reported that can
effectively predict those who are at risk for sudden
cardiac death despite improvement in EF, we should
continue to replace generators after a thorough dis-
cussion with the individual patient respecting his or
her preferences.*Jayasree Pillarisetti, MD
Madhu Yeruva Reddy, MD
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But the Scar Still Exists! The Risk
May Be Lower But Not ZeroWe thank Dr. Pillarisetti and colleagues for their in-
terest in our report (1). However, we disagree with the
conclusions they have drawn from additional analysis
of our data. They argue that patients with primary
prevention implantable cardioverter-deﬁbrillators
(ICDs) who experience no appropriate ICD therapy
and demonstrate improvement of left ventricular
ejection fraction (LVEF) to $40% should routinely
undergo generator replacement (GR). To further
this argument, they have analyzed the event rate
(appropriate ICD therapy) of 2.8% per person-year
that we observed in the group of patients who un-
derwent GR despite improved LVEF and have derived
a number needed to treat (NNT) of 76 to prevent 1
appropriate ICD therapy. They further contend that
the NNT may have been lower if patients who expe-
rienced appropriate ICD therapy despite improve-
ment in LVEF before GR were included. However,
their latter contention is invalid because in our
study these patients fulﬁlled secondary prevention
indications for ICD therapy. This point notwith-
standing, is an NNT of 76 to prevent 1 appropriate ICD
therapy sufﬁcient to justify routine GR?
In the largest trial assessing efﬁcacy of primary
prevention ICD therapy, i.e., SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) (2), the NNT with
ICD to prevent 1 death was 20. Similar NNTs have
been shown for other lifesaving advances in cardiol-
ogy that have gained widespread acceptance. For
example, the NNT with primary coronary angioplasty
(versus thrombolytic therapy) to prevent 1 death from
acute myocardial infarction is 10 (3), and the NNT
with beta-blockers in chronic heart failure to prevent
1 death is 15 (4). While it is unclear (and subjective)
what an “acceptable” NNT should be for GR in
recipients of primary prevention ICD, an NNT of 76 to
prevent 1 appropriate device therapy (which is not
synonymous with mortality) is clearly much higherthan what has been shown with other lifesaving car-
diovascular therapies. Furthermore, the potential
risks of the GR procedure must be taken into account.
Data from the REPLACE (Implantable Cardiac Pulse
Generator Replacement) registry show that the major
complication rate for patients undergoing ICD GR
is 5% (5). This would imply that for 1 patient to
receive appropriate ICD therapy after GR, 4 patients
would experience a major complication from the
procedure.
The principle of nonmaleﬁcence necessitates
weighing any lifesaving beneﬁt against the potential
for harm. The latter in patients undergoing ICD GR
includes inappropriate shocks, pocket or device in-
fections, device malfunction, and manufacturer re-
calls. Why an approach of LVEF reassessment and
informed discussion regarding the uncertain beneﬁts
and risks of GR in this patient population, as sug-
gested by our study, is perceived as “bold and
sweeping” by Dr. Pillarisetti and colleagues remains
unclear to us. In any situation in which there is sig-
niﬁcant uncertainty regarding the beneﬁts of a
treatment, deferring to patient preference after
sharing all the relevant information without bias is, in
our opinion, the optimal approach.Vinay Kini, MD
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